Turkoz I

Johnson & Johnson , , ,

5 papers

ArticleKetamine

ECHO: Results from a Non-Interventional Cohort Study of Esketamine Nasal Spray in Treatment Resistant Depression

Rosso G, Constant E, De Filippis S +12

Europe PMC2026
ArticleKetamine

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Ahmed M, Cabrera P, Doherty T +4

Europe PMC2026
ArticleKetamine

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval.

Sanacora G, Ahmed M, Brown B +11

Europe PMC2025
ArticleKetamine

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.

McIntyre RS, Mattingly G, Godinov Y +7

Europe PMC2025
ArticleKetamine

Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.

Kern Sliwa J, Naranjo RR Jr, Turkoz I +3

Europe PMC2024